Desenvolvimento e caraterização de nanopartículas poliméricas contendo grandisina

• Ano de defesa: 2011
• Autor(a) principal: STECANELLA, Luciano Aparecido
• Orientador(a): LIMA, Eliana Martins
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Goiás
• Programa de Pós-Graduação: Mestrado em Ciências Farmacêuticas
• Departamento: Ciências da Saúde - Farmácia
• País: BR
• Palavras-chave em Português: grandisina; nanocápsulas; PLGA
• Palavras-chave em Inglês: grandisin; nanocapsule; PLGA
• Área do conhecimento CNPq: CNPQ::CIENCIAS DA SAUDE::FARMACIA
• Link de acesso: http://repositorio.bc.ufg.br/tede/handle/tde/2118

Grandisin, a tetrahydrofuranic lignan produced by Virola surinamensis seeds and leaves, is popularly used to treat erysipelas, colic and dyspepsia, and is active against Schistosoma mansoni, Plasmodium falciparum, Leishmania donovani and Trypanosoma cruzi. It also antinociceptive, anti-inflamatory and potential for protective (dose dependent) activities, preventing cyclophosphamide induced chromosomal fragmentation, being considered a potencial anti-cancer candidate. The encapsulation of grandisin in polymeric nanocapsules can increase its solubility in aqueous media, allowing drug administration by intravenous route. In the presente work, polymeric nanocapsules containing grandisin were produced by nanoprecipitation method (or interfacial pre-formed polymer deposition). The average diameter of these nanocapsules were around 160 nm, PdI < 0,2, zeta potential -15,73 mV and grandisin load of 6,54%, with encapsulation efficiency of (EE%) 98%. Stability study, comprising 30 days under refrigeration (4ºC ± 1ºC), showed that physicochemical characteristics of the formulation (color, bluish translucency, etc.) were the same as compared to the nanocapsules dispersion originally produced, so there were no alterations such as deposition of residues and/or crystals, lumps formation, creamming or supernatant oil, droplets adhered to the glass, flocculation or phase separation. Regarding encapsulated grandisin, during stability test, there was a reduction of 6,4% of the total encapsulated drug. Drug release study showed quick liberation in the first 48h (30,54%) and then kept slower, because only 52% after 21 days. Polymeric nanocapsules containing grandisin, obtained in this work, showed potential to be a drug release system to administration by intravenous route.